When to Stop Immunotherapy Treatment for Melanoma

Video

Yania Jansen, surgical trainee at Vrije Universiteit Brussel, in Brussels, Belgium, discusses the possibility of stopping treatment with Keytruda (pembrolizumab) for patients with melanoma.

Yania Jansen, surgical trainee at Vrije Universiteit Brussel, in Brussels, Belgium, discusses the possibility of stopping treatment with Keytruda (pembrolizumab) for patients with melanoma.

When the patient is responding to Keytruda and there is no more evidence of progression, discontinuing treatment is a decision that must be made by the patient and physician together, taking into consideration future treatment plans should the disease progress, as well as the goals of the patient. Many may want to stop the drug to avoid side effects and improve quality of life.

Jansen conducted a study including 509 patients with melanoma being treated with Keytruda. After more than a year of treatment, 81 patients decided to stop. Two experienced disease relapses -- the first patient decided to start Keytruda again and showed a new response, while the second started a different treatment regimen.

Related Videos
Image of a woman with a brown hair tied into a bun.
Image of Annie Bond.
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Image of Dr. Minesh Mehta at ASCO 2024.
Image of a woman with blond hai
Related Content